Optimization of Drug Prescriptions in the Care Pathway for the Elderly, With the Final Objective of Reducing the Iatrogenic Risk
NCT ID: NCT05045235
Last Updated: 2025-11-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
1500 participants
OBSERVATIONAL
2021-09-01
2025-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Collaborative Approach to Medication Reviews for Older Patients With Polypharmacy
NCT03909035
Iatrogenic Drug Risk in People Over 75, With or Without Cognitive Disorders, From an Inventory of Their Family Pharmacy
NCT03686943
Comprehensive Management of Drug Prescriptions Throughout the Elderly Person's Hospital Care
NCT03666793
Optimization of Drug Prescribing in an Elderly Population of Geriatric Consultations
NCT02740764
A Trial to De-prescribe Inappropriate Medications in the Community Dwelling Elderly
NCT02053194
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Potential involvement of a drug in hospitalization or potential or proven iatrogenic event during hospitalization;
* Numerous therapeutic modifications (3 or more);
* Drug interaction or introction of a new drug with one or more drug interactions;
* Medicinal product with a narrow therapeutic marge drug requiring close monitoring.
Exclusion Criteria
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centre Hospitalier Universitaire, Amiens
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Amiens University Hospital
Amiens, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PI2021_843_0158
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.